# TestCard

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/testcard

- Industry: Healthcare IT
- Headquarters: Scarborough, UK
- Website: www.testcard.com
- Total disclosed funding: $1.6M
- Latest round: Seed (Sep 30, 2019)
- Investors on record: 3

## About

TestCard Ltd. develops innovative digital diagnostic testing solutions, enabling accurate health assessments through its ClearScreen platform. It transforms smartphone cameras into clinical-grade scanners for various medical tests, enhancing accessibility and efficiency in healthcare delivery.TestCard Ltd. was founded in 2017 in Scarborough, UK, focusing on digital health solutions. The company has pivoted to enhance its product offerings, particularly through the ClearScreen platform, which allows for the efficient reading and reporting of test results using smart devices. The founders include Andrew Botham, Lucas Heron, and Luke Heron, with Chris Craig-Wood serving as the CEO. In April 2022, the company raised USD 10 mn in a funding round led by West Hill Capital, bringing the total amount raised to USD 10 mn. TestCard has engaged in 4 investment deals to date, the most recent occurring in April 2022.TestCard specializes in digital diagnostic testing solutions, primarily through its flagship product, the ClearScreen platform. This innovative technology transforms camera-enabled smart devices into clinical-grade scanners capable of accurate reading, recording, and reporting of test results. The ClearScreen app is designed for both healthcare professionals and laypersons, ensuring ease of use in various settings, including hospitals, clinics, and at-home testing environments. The company has established partnerships with key players such as the NHS and Roche, making its services accessible across the UK and other international markets, adapting to the needs of patients, healthcare providers, and research organizations. TestCard's offerings are particularly aimed at improving accessibility, affordability, and accuracy in point-of-care testing, with services that cater to multiple demographics, including individuals undergoing pre-procedure screenings and those in need of routine health checks.TestCard generates revenue through partnerships and subscriptions related to its diagnostic technology services, specifically the ClearScreen platform. The company engages in B2B transactions, collaborating with healthcare institutions and organizations such as the NHS and Roche, while also providing at-home testing solutions directly to consumers. Revenue streams include licensing fees for the use of the ClearScreen technology, support services, integration of their app into existing medical systems, and provisions for necessary hardware. These transactions are structured to facilitate seamless implementation and ongoing support, allowing healthcare providers to utilize TestCard’s technology effectively within their workflows. The company’s revenue model is bolstered by its commitment to regular updates and enhancements based on user feedback, ensuring sustained value for its clients and end users.In April 2022, TestCard Ltd. raised USD 10 mn in venture funding led by West Hill Capital. The company plans to use this investment to further commercialize its existing product portfolio and launch new testing products, including diabetes, pregnancy, chronic kidney disease (CKD), and flu testing. TestCard aims to expand its market presence, targeting additional regions to enhance its service accessibility and effectiveness.

## Funding rounds

- Seed, Sep 30, 2019 — Plug and Play, Parkpine Capital
- Seed, Feb 26, 2018, $1.6M — Neo Ventures

## Investors

- Neo Ventures — Seed
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- Parkpine Capital (https://capitalatlas.ai/funds/parkpine-capital) — Seed